Interleukin-4 in Pityriasis Lichenoides Chronica

NCT ID: NCT06889506

Last Updated: 2025-03-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-01

Study Completion Date

2025-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

assessment of the level of interleukin 4 (IL-4) in the lesional skin and serum of PLC patients and compare its level with healthy controls.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

measuring the level of Interleukin 4 in lesional skin and it's serum level using ELIZA in patients with Pityriasis lichenoides chronica and comparing the levels with healthy controls levels

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pityriasis Lichenoides

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PLC patients

one skin biopsy (lesional) and serum sample will be taken from every patient

Group Type ACTIVE_COMPARATOR

skin biopsy and serum sample

Intervention Type PROCEDURE

skin biopsy from lesional skin and serum sample will be taken from each patient . also a skin biopsy and serum sample will be taken from each healthy control

healthy controls

a skin biopsy and serum sample will be taken from each control sample

Group Type EXPERIMENTAL

skin biopsy and serum sample

Intervention Type PROCEDURE

skin biopsy from lesional skin and serum sample will be taken from each patient . also a skin biopsy and serum sample will be taken from each healthy control

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

skin biopsy and serum sample

skin biopsy from lesional skin and serum sample will be taken from each patient . also a skin biopsy and serum sample will be taken from each healthy control

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with pityriasis lichenoides Chronica (PLC): either with the classical presentation papular or hypo-pigmented macules and patches that proved histopathologically to be PLC.
* Both genders
* Age group ≥ 8 years

Exclusion Criteria

* Patients with other skin diseases
* Patient received treatment for PLC within period less than three months
* Pregnant patients
* Lactating patients
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mona Mostafa Korany Mahmoud

principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Dermatology 20

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.